Subclinical alteration of taste sensitivity induced by candesartan in healthy subjects

British Journal of Clinical Pharmacology

Volumn 57, Issue 6, 2004, Pages 807-812

  Tsuruoka, Shuichi ^a   Wakaumi, Michi ^a   Nishiki, Kenta ^a   Araki, Nobutaka ^a   Harada, Kenichi ^a   Sugimoto, Koichi ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adverse reactions; Angiotensin II receptor blockers; Dysgeusia; Gustometry

Indexed keywords

ANGIOTENSIN RECEPTOR; CANDESARTAN HEXETIL; LOSARTAN; VALSARTAN; ZINC;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FUNCTION TEST; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TASTE ACUITY; TASTE BUD; TASTE DISCRIMINATION; TASTE DISORDER; ZINC BLOOD LEVEL;

ADULT; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; SENSORY THRESHOLDS; TASTE DISORDERS; TETRAZOLES;

EID: 2942612191     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2003.02063.x     Document Type: Article

References (20)

1. Zegarelli D. Diseases of oral mucosa. In Avery's drug treatment, eds. Speight TN, Holford N. Auckland: Adis International, 1997; pp. 608-30.
2. Henkin RI. Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Saf 1994; 11: 318-77.
3. Tomita H, Yoshikawa T. Drug-related taste disturbances. Acta Otolaryngol Suppl 2002; 546: 116-21.
4. Heyneman CA. Zinc deficiency and taste disorders. Ann Pharmacother 1996; 30: 186-7.
5. Kaplan N. Treatment of hypertension: drug therapy. In Clinical Hypertension, ed. Kaplan, N. Baltimore: Williams & Wilkins, 1998; p. 181-264.
6. Schlienger RG, Saxer M, Haefeli WE. Reversible ageusia associated with losartan. Lancet 1996; 347: 471-2.
7. Heeringa M, van Puijenbroek EP. Reversible dysgeusia attributed to losartan. Ann Intern Med 1998; 129: 72.
8. Ohkoshi N, Shoji S. Reversible ageusia induced by losartan: a case report. Eur J Neurol 2002; 9: 315.
9. Stroeder R, Zeissig L. Angiotensin II-antagonist cGP48933 (valsartan), Ergebnisse einer doppelblinden, plazebo-Kontrolierten Multicenter-Studie. Nieren Hochdruckkrankheiten) 1994; 23: 217-20. (in German).
10. Meret S, Henkin R. Simultaneous direct estimation by atomic absorption spectrophotometry of copper and zinc in serum, urine, and cerebrospinal fluid. Clin Chem 1971; 17: 369-73.
11. Stenhoff H, Lagerstrom P, Andersen C. Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection. J Chromatogr B Biomed Sci Appl 1999; 731: 411-17.
12. Kuga M, Ikeda M. Evaluation of gustatory threshold changes in healthy subjects. Nippon Jibiinkoka Gakkai Kaiho 1996; 99: 411-16.
13. Tomita H, Ikeda M, Okuda Y. Basis and practice of clinical taste examinations. Auris Nasus Larynx 1986; 13(Suppl 1): S1-S15.
14. Sato K, Endo S, Tomita H. Sensitivity of three loci on the tongue and soft palate to four basic tastes in smokers and non-smokers. Acta Otolaryngol Suppl 2002; 546: 74-82.
15. Tomita H, Ikeda M. Clinical use of electrogustometry: strengths and limitations. Acta Otolaryngol Suppl 2002; 546: 27-38.
16. Schiffman S. Taste and smell in disease. New Engl J Med 1983; 308: 1275-9.
17. Erilssen J, Saegaard E, Naess J. Side-effect of thiocarbamide. Lancet 1975; ii: 231-2.
18. Gilbertson T, Damak S, Margolskee R. The molecular physiology of taste transduction. Curr Opin Neurobiol 2000; 10: 519-27.
19. Lindemann B. Receptors and transduction in taste. Nature (Lond) 2001; 413: 219-25.
20. Bockaert J, Pin J. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999; 18: 1723-9.